Anemia in CKD: Stage of Onset According to KDIGO
Anemia in chronic kidney disease typically becomes clinically significant starting at CKD Stage 3 (eGFR <60 mL/min/1.73 m²), with prevalence and severity increasing progressively through Stages 4 and 5. 1
Prevalence by CKD Stage
CKD Stage 1-2 (eGFR >60 mL/min/1.73 m²): Anemia prevalence is relatively low in the general population at these stages, though it can occur in high-risk patients with diabetes, hypertension, or family history of kidney disease 1
CKD Stage 3 (eGFR 30-59 mL/min/1.73 m²): Mean hemoglobin levels begin to decrease consistently when GFR falls below 60 mL/min/1.73 m², marking the stage where anemia becomes a regular clinical concern 1
CKD Stage 4 (eGFR 15-29 mL/min/1.73 m²): Anemia prevalence increases dramatically, affecting 22-52% of patients depending on diabetes status 2. The KDIGO guidelines specifically note that clinical trials in CKD stages 3 and 4 (CHOIR and CREATE) focused on this population due to the clinical significance of anemia at these stages 3
CKD Stage 5 (eGFR <15 mL/min/1.73 m²): Anemia prevalence reaches 50-53%, with the highest severity of anemia observed at this stage 1
Key Clinical Considerations
Diabetic patients develop anemia earlier and more severely compared to non-diabetic CKD patients at equivalent stages of kidney function 1. At Stage 3, diabetic patients show 7.5% prevalence versus 5.0% in non-diabetics, and at Stage 4, the difference is even more pronounced (22.2% versus 7.9%) 1.
Significant variability exists in hemoglobin levels at any given level of kidney function, meaning some patients may develop anemia earlier or later than the typical pattern 1. This underscores why KDIGO recommends measuring hemoglobin at least annually in all CKD patients regardless of stage 4.
KDIGO Monitoring Recommendations
The frequency of hemoglobin monitoring escalates with CKD stage 4:
- CKD Stage 3: Measure hemoglobin at least annually in patients without anemia 4
- CKD Stage 4-5 (non-dialysis): Measure at least twice per year 4
- CKD Stage 5 (dialysis): Measure at least every 3 months 4
Once anemia is detected, monitoring frequency increases to every 3 months for CKD stages 3-5 not on dialysis, and monthly for dialysis patients 4, 2.
Diagnostic Thresholds
KDIGO defines anemia in adults with CKD as hemoglobin <13.0 g/dL in males and <12.0 g/dL in females 4. These thresholds should trigger further evaluation and consideration of treatment, particularly as patients progress to Stage 3 and beyond where anemia becomes increasingly prevalent and clinically significant.